Citations

Citations to this article as recorded by  

• Tumor-associated microenvironment, PD-L1 expression and their relationship with immunotherapy in glioblastoma, IDH-wild type: A comprehensive review with emphasis on the implications for neuropathologists
  Giuseppe Broggi, Giuseppe Angelico, Jessica Farina, Giordana Tinnirello, Valeria Barresi, Magda Zanelli, Andrea Palicelli, Francesco Certo, Giuseppe Barbagallo, Gaetano Magro, Rosario Caltabiano
  Pathology - Research and Practice.2024; 254: 155144.     CrossRef
• Treatment advances in high-grade gliomas
  Xi Chen, Yi Cui, Liqun Zou
  Frontiers in Oncology.2024;[Epub]     CrossRef
• TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors
  Joshua R. D. Pearson, Carles Puig-Saenz, Jubini E. Thomas, Lydia D. Hardowar, Murrium Ahmad, Louise C. Wainwright, Adam M. McVicar, Victoria A. Brentville, Chris J. Tinsley, A. Graham Pockley, Lindy G. Durrant, Stephanie E. B. McArdle
  Cancer Immunology, Immunotherapy.2024;[Epub]     CrossRef
• Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
  Berta Segura-Collar, Sara Hiller-Vallina, Olaya de Dios, Marta Caamaño-Moreno, Lucia Mondejar-Ruescas, Juan M. Sepulveda-Sanchez, Ricardo Gargini
  Acta Neuropathologica Communications.2023;[Epub]     CrossRef
• Immunohistochemical Analysis of PD-1 and FOXP3 in Tumor-Infiltrating Lymphocytes in Human Gliomas
  Priyanka Kanagaraj, Archana Balasubramanian, Raveena Suresh, Bhargavi Somasundaram, Sandhya Sundaram, Priyathersini Nagarajan
  Cureus.2023;[Epub]     CrossRef
• Expression, prognostic significance and therapeutic implications of PD‐L1 in gliomas
  Gayaththri Vimalathas, Bjarne Winther Kristensen
  Neuropathology and Applied Neurobiology.2022;[Epub]     CrossRef
• PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma
  Carolina Noronha, Ana Sofia Ribeiro, Ricardo Taipa, Dina Leitão, Fernando Schmitt, Joaquim Reis, Cláudia Faria, Joana Paredes
  Journal of Neuro-Oncology.2022; 156(3): 453.     CrossRef
• Assessment of radiographic and prognostic characteristics of programmed death-ligand 1 expression in high-grade gliomas
  Makoto Ohno, Shigehisa Kitano, Kaishi Satomi, Akihiko Yoshida, Yasuji Miyakita, Masamichi Takahashi, Shunsuke Yanagisawa, Yukie Tamura, Koichi Ichimura, Yoshitaka Narita
  Journal of Neuro-Oncology.2022; 160(2): 463.     CrossRef
• The prognostic significance of PD-L1 expression in patients with glioblastoma: A meta-analysis
  Xin Guo, Yuelin Zhang, Hengxing Jiao, Xingyu Miao
  Frontiers in Oncology.2022;[Epub]     CrossRef
• LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway
  Xiaoming Wang, Yan Zhang, Jian Zheng, Cuixian Yao, Xiubo Lu
  Cancer Immunology, Immunotherapy.2021; 70(8): 2235.     CrossRef
• Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma
  Kelsey Maddison, Moira C. Graves, Nikola A. Bowden, Michael Fay, Ricardo E. Vilain, Sam Faulkner, Paul A. Tooney
  Oncotarget.2021; 12(21): 2177.     CrossRef
• A Systematic Review of the Tumor-Infiltrating CD8+ T-Cells/PD-L1 Axis in High-Grade Glial Tumors: Toward Personalized Immuno-Oncology
  Mahdi Abdoli Shadbad, Zahra Asadzadeh, Negar Hosseinkhani, Afshin Derakhshani, Nazila Alizadeh, Oronzo Brunetti, Nicola Silvestris, Behzad Baradaran
  Frontiers in Immunology.2021;[Epub]     CrossRef
• Prognostic value of programmed death ligand 1 (PD-L1) in glioblastoma: a systematic review, meta-analysis and validation based on dataset
  Huan Wang, Youchao Xiao, Xingguang Ren, Dahai Wan
  Bioengineered.2021; 12(2): 10366.     CrossRef
• Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma
  Nyall R. London, Lisa M. Rooper, Justin A. Bishop, Haiying Xu, Lydia J. Bernhardt, Masaru Ishii, Christine L. Hann, Janis M. Taube, Evgeny Izumchenko, Daria A. Gaykalova, Gary L. Gallia
  World Neurosurgery.2020; 135: e187.     CrossRef
• CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas
  Joseph A. Flores-Toro, Defang Luo, Adithya Gopinath, Matthew R. Sarkisian, James J. Campbell, Israel F. Charo, Rajinder Singh, Thomas J. Schall, Meenal Datta, Rakesh K. Jain, Duane A. Mitchell, Jeffrey K. Harrison
  Proceedings of the National Academy of Sciences.2020; 117(2): 1129.     CrossRef
• Treatment Results for Recurrent Glioblastoma and Alteration of Programmed Death-Ligand 1 Expression After Recurrence
  Kyoung Su Sung, Tae Hoon Roh, Ju Hyung Moon, Eui Hyun Kim, Seok-Gu Kang, Se Hoon Kim, Jong Hee Chang
  World Neurosurgery.2020; 135: e459.     CrossRef
• Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma
  Chang Shu, Qingguo Li
  Critical Reviews in Oncology/Hematology.2020; 151: 102965.     CrossRef
• PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis
  Chengcheng Hao, Gang Chen, Huishan Zhao, Yan Li, Jianxin Chen, Hongmei Zhang, Shan Li, Yuze Zhao, Feng Chen, Wenbin Li, Wen G. Jiang
  Frontiers in Oncology.2020;[Epub]     CrossRef
• Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook
  Patrick C. Gedeon, Cosette D. Champion, Kristen E. Rhodin, Karolina Woroniecka, Hanna R. Kemeny, Alexa N. Bramall, Joshua D. Bernstock, Bryan D. Choi, John H. Sampson
  Expert Review of Clinical Pharmacology.2020; 13(10): 1147.     CrossRef
• Current clinical management of elderly patients with glioma
  Alessia Pellerino, Francesco Bruno, Valeria Internò, Roberta Rudà, Riccardo Soffietti
  Expert Review of Anticancer Therapy.2020; 20(12): 1037.     CrossRef
• The Prognostic and Therapeutic Value of PD-L1 in Glioma
  Ruo Qiao Chen, Feng Liu, Xin Yao Qiu, Xiao Qian Chen
  Frontiers in Pharmacology.2019;[Epub]     CrossRef
• Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
  Xin Wang, Gaochao Guo, Hui Guan, Yang Yu, Jie Lu, Jinming Yu
  Journal of Experimental & Clinical Cancer Research.2019;[Epub]     CrossRef
• Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma
  Xiao Shi, Peng-Cheng Yu, Bo-Wen Lei, Cui-Wei Li, Yan Zhang, Li-Cheng Tan, Rong-Liang Shi, Jie Wang, Ben Ma, Wei-Bo Xu, Xiao Wang, Jia-Qian Hu, Nai-Si Huang, Wen-Jun Wei, Yu Wang, Tong-Zhen Chen, Yu-Long Wang, Qing-Hai Ji
  Thyroid.2019; 29(9): 1269.     CrossRef
• The Binding of PD-L1 and Akt Facilitates Glioma Cell Invasion Upon Starvation via Akt/Autophagy/F-Actin Signaling
  Ruo Qiao Chen, Xiao Hong Xu, Feng Liu, Chun Yang Li, Yuan Jun Li, Xiang Rui Li, Guo Yong Jiang, Feng Hu, Di Liu, Feng Pan, Xin Yao Qiu, Xiao Qian Chen
  Frontiers in Oncology.2019;[Epub]     CrossRef
• Analysis of PD-L1 expression in salivary duct carcinoma with its efficacy as a tumor marker
  Yong Ju Lee, Yoon Woo Koh, Sun Och Yoon, Hyang Joo Ryu, Hye Ryun Kim, Hyang Ae Shin
  Korean Society for Head and Neck Oncology.2019; 35(1): 13.     CrossRef
• Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma
  Kyu Sang Lee, Kyoungyul Lee, Sumi Yun, Seyoung Moon, Yujun Park, Jung Ho Han, Chae-Yong Kim, Hye Seung Lee, Gheeyoung Choe
  Journal of Neuro-Oncology.2018; 136(3): 453.     CrossRef
• Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma
  Hyo Jung An, Gyung Hyuck Ko, Jeong-Hee Lee, Jong Sil Lee, Dong Chul Kim, Jung Wook Yang, Min Hye Kim, Jin Pyeong Kim, Eun Jung Jung, Dae Hyun Song
  Journal of Pathology and Translational Medicine.2018; 52(1): 9.     CrossRef
• Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?
  Michele Porcu, Cinzia Solinas, Paolo Garofalo, Evandro de Azambuja, Mario Scartozzi, Karen Willard-Gallo, Matthias Preusser, Luca Saba
  Critical Reviews in Oncology/Hematology.2018; 126: 135.     CrossRef
• The expression of programed death ligand‐1 could be related with unfavorable prognosis in salivary duct carcinoma
  Fumihiko Sato, Jun Akiba, Akihiko Kawahara, Yoshiki Naito, Takeharu Ono, Yorihiko Takase, Kazuya Murata, Hideyuki Abe, Tomohiko Yamaguchi, Hiroaki Miyoshi, Yushi Abe, Yutaro Mihara, Masahiko Tanikawa, Momoko Akashi, Hirofumi Kurose, Hirohito Umeno, Hirohi
  Journal of Oral Pathology & Medicine.2018; 47(7): 683.     CrossRef
• Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma
  Dwight Owen, Benjamin Chu, Amy M. Lehman, Lakshmanan Annamalai, Jennifer H. Yearley, Konstantin Shilo, Gregory A. Otterson
  Journal of Thoracic Oncology.2018; 13(8): 1204.     CrossRef
• PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies
  Noah Frydenlund, Meera Mahalingam
  Human Pathology.2017; 66: 13.     CrossRef
• Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma
  Russell Maxwell, Christopher M. Jackson, Michael Lim
  Current Treatment Options in Oncology.2017;[Epub]     CrossRef
• Topotecan Decreases the Expression of Programmed Death-Ligand 1 in Glioblastoma Cell Lines; Implications for Immunotherapy
  Joshua Bernstock, Daniel Ye, Florian Gessler, Luca Peruzzotti-Jametti, Mark Gilbert, Yves Pommier, Stefano Pluchino, Ichiro Nakano, John Hallenbeck
  Matters.2017;[Epub]     CrossRef
• Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma
  Song Xue, Man Hu, Peifeng Li, Ji Ma, Li Xie, Feifei Teng, Yufang Zhu, Bingjie Fan, Dianbin Mu, Jinming Yu
  Oncotarget.2017; 8(30): 49702.     CrossRef